Sweden In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Introduction

GlobalData’s new report, “Sweden In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Sweden In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Sweden In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, bioMerieux S.A., Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc. and others.

Highlights

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Sweden In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Report Highlights
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
bioMerieux S.A.
Ortho-Clinical Diagnostics Inc.
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Becton, Dickinson and Company
Sysmex Corporation
DiaSorin S.p.A
Phadia AB
Qiagen N.V.
HORIBA, Ltd.
DIAGNOSTICA STAGO, Inc.
Gen-Probe Incorporated
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Grifols, S.A.
Cellestis Limited
Hologic, Inc.
Immucor, Inc.
Danaher Corporation
Life Technologies Corporation
[Studien Infos ausblenden]

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics In Sweden 16
3.1 In Vitro Diagnostics, Market Segmentation 16
3.2 In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, 2003-2017 17
3.3 In Vitro Diagnostics Market, Sweden, Revenue Mix ($m), 2010 19
3.4 In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2010 20
3.5 In Vitro Diagnostics, Sweden, Company share (2009-2010) 27
4 Clinical Chemistry In Sweden 29
4.1 Clinical Chemistry, Market Segmentation 29
4.2 Clinical Chemistry Market, Sweden, Revenue Mix ($m), 2010 30
4.3 Clinical Chemistry Market, Sweden, Segment Contribution (%), 2010 31
4.4 Clinical Chemistry Overall Revenue (2003-2017) 32
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 36
4.4.2 Urine Analysis Revenue (2003-2017) 40
4.5 Clinical Chemistry Distribution Share (2009-2010) 44
4.6 Clinical Chemistry, Sweden, Company share (2009-2010) 45
5 Genetic Testing In Sweden 47
5.1 Genetic Testing, Market Segmentation 47
5.2 Genetic Testing Market, Sweden, Revenue Mix ($m), 2010 48
5.3 Genetic Testing Market, Sweden, Segment Contribution (%), 2010 49
5.4 Genetic Testing Overall Revenue (2003-2017) 50
5.5 Genetic Testing Distribution Share (2009-2010) 54
5.6 Genetic Testing, Sweden, Company share (2009-2010) 55
6 Haematology In Sweden 57
6.1 Haematology, Market Segmentation 57
6.2 Haematology Market, Sweden, Revenue Mix ($m), 2010 58
6.3 Haematology Market, Sweden, Segment Contribution (%), 2010 59
6.4 Haematology Overall Revenue (2003-2017) 60
6.4.1 Haematology Reagents Revenue (2003-2017) 64
6.4.2 Immunohaematology Revenue (2003-2017) 68
6.4.3 Haemostasis Revenue (2003-2017) 72
6.4.4 Haematology Rapid Tests Revenue (2003-2017) 76
6.4.5 Haematology Cell Counters Revenue (2003-2017) 80
6.5 Haematology Distribution Share (2009-2010) 84
6.6 Haematology, Sweden, Company share (2009-2010) 85
7 Histology And Cytology In Sweden 87
7.1 Histology And Cytology, Market Segmentation 87
7.2 Histology And Cytology Market, Sweden, Revenue Mix ($m), 2010 88
7.3 Histology And Cytology Market, Sweden, Segment Contribution (%), 2010 89
7.4 Histology And Cytology Overall Revenue (2003-2017) 90
7.5 Histology And Cytology Distribution Share (2009-2010) 94
7.6 Histology And Cytology, Sweden, Company share (2009-2010) 95
8 Immuno Chemistry In Sweden 97
8.1 Immuno Chemistry Market, Sweden, Revenue Mix ($m), 2010 97
8.2 Immuno Chemistry Market, Sweden, Segment Contribution (%), 2010 98
8.3 Immuno Chemistry Overall Revenue (2003-2017) 99
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 103
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 107
8.3.3 Endocrinology Tests Revenue (2003-2017) 111
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 115
8.3.5 Immunochemistry Analyzers Revenue (2003-2017) 119
8.4 Immuno Chemistry Distribution Share (2009-2010) 123
8.5 Immuno Chemistry, Sweden, Company share (2009-2010) 124
9 Infectious Immunology In Sweden 126
9.1 Infectious Immunology, Market Segmentation 126
9.2 Infectious Immunology Market, Sweden, Revenue Mix ($m), 2010 127
9.3 Infectious Immunology Market, Sweden, Segment Contribution (%), 2010 128
9.4 Infectious Immunology Overall Revenue (2003-2017) 129
9.5 Infectious Immunology Distribution Share (2009-2010) 133
9.6 Infectious Immunology, Sweden, Company share (2009-2010) 134
10 Microbiology Culture In Sweden 136
10.1 Microbiology Culture, Market Segmentation 136
10.2 Microbiology Culture Market, Sweden, Revenue Mix ($m), 2010 137
10.3 Microbiology Culture Market, Sweden, Segment Contribution (%), 2010 138
10.4 Microbiology Culture Overall Revenue (2003-2017) 139
10.4.1 Microbiology Analyzers Revenue (2003-2017) 143
10.5 Microbiology Culture Distribution Share (2009-2010) 147
10.6 Microbiology Culture, Sweden, Company share (2009-2010) 148
11 Overview of Key Companies in Sweden In Vitro Diagnostics Market 150
11.1 F. Hoffmann-La Roche Ltd. 150
11.1.1 Company Overview 150
11.1.2 Share in the Sweden In Vitro Diagnostics Market 150
11.2 Siemens Healthcare 151
11.2.1 Company Overview 151
11.2.2 Share in the Sweden In Vitro Diagnostics Market 151
11.3 Abbott Laboratories 152
11.3.1 Company Overview 152
11.3.2 Share in the Sweden In Vitro Diagnostics Market 152
11.4 bioMerieux S.A. 153
11.4.1 Company Overview 153
11.4.2 Share in the Sweden In Vitro Diagnostics Market 153
11.5 Ortho-Clinical Diagnostics Inc. 154
11.5.1 Company Overview 154
11.5.2 Share in the Sweden In Vitro Diagnostics Market 154
11.6 Beckman Coulter, Inc. 155
11.6.1 Company Overview 155
11.6.2 Share in the Sweden In Vitro Diagnostics Market 155
11.7 Bio-Rad Laboratories, Inc. 156
11.7.1 Company Overview 156
11.8 Becton, Dickinson and Company 156
11.8.1 Company Overview 156
11.9 Sysmex Corporation 156
11.9.1 Company Overview 156
11.10 DiaSorin S.p.A 157
11.10.1 Company Overview 157
11.11 Phadia AB 157
11.11.1 Company Overview 157
11.12 Qiagen N.V. 157
11.12.1 Company Overview 157
11.13 HORIBA, Ltd. 158
11.13.1 Company Overview 158
11.14 DIAGNOSTICA STAGO, Inc. 158
11.14.1 Company Overview 158
11.15 Gen-Probe Incorporated 158
11.15.1 Company Overview 158
11.16 PerkinElmer, Inc. 159
11.16.1 Company Overview 159
11.17 Thermo Fisher Scientific Inc. 159
11.17.1 Company Overview 159
11.18 Grifols, S.A. 160
11.18.1 Company Overview 160
11.19 Cellestis Limited 160
11.19.1 Company Overview 160
11.20 Hologic, Inc. 161
11.20.1 Company Overview 161
11.21 Immucor, Inc. 161
11.21.1 Company Overview 161
11.22 Danaher Corporation 161
11.22.1 Company Overview 161
11.23 Life Technologies Corporation 162
11.23.1 Company Overview 162
12 In Vitro Diagnostics Market Pipeline Products 163
12.1 Clinical Chemisty Market Pipeline Products 163
12.2 Immuno Chemistry Market Pipeline Products 166
12.3 Haematology Market Pipeline Products 169
12.4 Infectious Immunology Market Pipeline Products 171
12.5 Microbiology Culture Market Pipeline Products 174
12.6 Histology And Cytology Market Pipeline Products 175
12.7 Genetic Testing Market Pipeline Products 176
13 Financial Deals Landscape 179
13.1 Acquisition 179
13.1.1 Thermo Fisher Completes Acquisition Of Phadia 179
13.1.2 AlphaHelix Molecular Diagnostics Acquires Techtum Lab 181
13.1.3 Addtech Life To Acquire Electra-Box Diagnostica 182
13.2 Partnerships 183
13.2.1 Biofortuna Enters Into Distribution Agreement With Abbott 183
13.2.2 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 184
14 Recent Developments 185
14.1 Legal and Regulatory 185
14.1.1 May 09, 2011: Biotage Announces USPTO Rejects All Claims In US Patent 7,138,061 185
14.2 Product News 185
14.2.1 Oct 12, 2011: AbSorber Obtains US Patent For Cross Match-Test XM-ONE 185
14.2.2 Sep 27, 2011: FDA Clears CellaVision Body Fluid Application For CellaVision DM1200 Cell Morphology System 186
14.2.3 May 26, 2011: Study Affirms Clinical Utility Of Phadia’s ImmunoCAP Specific IgE Blood Test: Quest 187
14.2.4 May 11, 2011: New Study Confirms That XM-ONE Identifies Kidney Transplant Recipients At Increased Risk For Acute Rejection 188
14.2.5 Mar 18, 2011: Phadia Demonstrates Benefit Of ImmunoCAP Molecular Allergy Test Results At AAAAI Annual Meeting 188
15 Appendix 190
15.1 Definitions of Markets Covered in the Report 191
15.1.1 In Vitro Diagnostics 191
15.2 Research Methodology 202
15.3 Secondary Research 202
15.4 Primary Research 203
15.5 Models 203
15.6 Forecasts 204
15.7 Expert Panels 204
15.8 GlobalData Consulting 204
15.9 Currency Conversion 205
15.10 Contact Us 205
15.11 Disclaimer 205
[Inhaltsverzeichnis ausblenden]

1.1 List of Tables
Table 1: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, 2003-2017 18
Table 2: In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2010 20
Table 3: In Vitro Diagnostics, Sweden, Cross-Category Analysis, 2003-2017 22
Table 4: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, Historic, 2003-2010 24
Table 5: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 26
Table 6: In Vitro Diagnostics, Sweden, Company share by Revenue ($m), USD Actual, 2009-2010 28
Table 7: Clinical Chemistry Market, Sweden, Segment Contribution (%), 2010 31
Table 8: Clinical Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 33
Table 9: Clinical Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 35
Table 10: Clinical Chemisty Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 37
Table 11: Clinical Chemisty Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 39
Table 12: Urine Analysis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 41
Table 13: Urine Analysis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 43
Table 14: Clinical Chemistry, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44
Table 15: Clinical Chemistry, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 46
Table 16: Genetic Testing Market, Sweden, Segment Contribution (%), 2010 49
Table 17: Genetic Testing, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 51
Table 18: Genetic Testing, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 53
Table 19: Genetic Testing, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 54
Table 20: Genetic Testing, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 56
Table 21: Haematology Market, Sweden, Segment Contribution (%), 2010 59
Table 22: Haematology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 61
Table 23: Haematology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 63
Table 24: Haematology Reagents, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 65
Table 25: Haematology Reagents, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 67
Table 26: Immunohaematology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 69
Table 27: Immunohaematology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 71
Table 28: Haemostasis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 73
Table 29: Haemostasis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 75
Table 30: Haematology Rapid Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 77
Table 31: Haematology Rapid Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 79
Table 32: Haematology Cell Counters, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81
Table 33: Haematology Cell Counters, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83
Table 34: Haematology, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 84
Table 35: Haematology, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 86
Table 36: Histology And Cytology Market, Sweden, Segment Contribution (%), 2010 89
Table 37: Histology And Cytology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 91
Table 38: Histology And Cytology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 93
Table 39: Histology And Cytology, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94
Table 40: Histology And Cytology, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 96
Table 41: Immuno Chemistry Market, Sweden, Segment Contribution (%), 2010 98
Table 42: Immuno Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 100
Table 43: Immuno Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 102
Table 44: Disease Specific Immunochemistry, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 104
Table 45: Disease Specific Immunochemistry, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 106
Table 46: Drugs of Abuse / Toxicology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 108
Table 47: Drugs of Abuse / Toxicology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 110
Table 48: Endocrinology Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 112
Table 49: Endocrinology Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 114
Table 50: Therapeutic Drug Monitoring, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 116
Table 51: Therapeutic Drug Monitoring, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 118
Table 52: Immunochemistry Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 120
Table 53: Immunochemistry Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 122
Table 54: Immuno Chemistry, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 123
Table 55: Immuno Chemistry, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 125
Table 56: Infectious Immunology Market, Sweden, Segment Contribution (%), 2010 128
Table 57: Infectious Immunology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 130
Table 58: Infectious Immunology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 132
Table 59: Infectious Immunology, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 133
Table 60: Infectious Immunology, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 135
Table 61: Microbiology Culture Market, Sweden, Segment Contribution (%), 2010 138
Table 62: Microbiology Culture, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 140
Table 63: Microbiology Culture, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 142
Table 64: Microbiology Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 144
Table 65: Microbiology Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 146
Table 66: Microbiology Culture, Sweden, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147
Table 67: Microbiology Culture, Sweden, Company share by Revenue ($m), USD Actual 2009-2010 149
Table 68: Clinical Chemisty Market Pipeline Products 163
Table 69: Immuno Chemistry Market Pipeline Products 166
Table 70: Haematology Market Pipeline Products 169
Table 71: Infectious Immunology Market Pipeline Products 171
Table 72: Microbiology Culture Market Pipeline Products 174
Table 73: Histology And Cytology Market Pipeline Products 175
Table 74: Genetic Testing Market Pipeline Products 176
Table 75: Thermo Fisher Completes Acquisition Of Phadia 179
Table 76: AlphaHelix Molecular Diagnostics Acquires Techtum Lab 181
Table 77: Addtech Life To Acquire Electra-Box Diagnostica 182
Table 78: Biofortuna Enters Into Distribution Agreement With Abbott 183
Table 79: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 184
Table 80: USD to Local Currency, Sweden, Average Actual Rate 2003-2010 205
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation 16
Figure 2: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, 2003-2017 17
Figure 3: In Vitro Diagnostics Market, Sweden, Revenue Mix ($m), 2010 19
Figure 4: In Vitro Diagnostics Market, Sweden, Category Contribution (%), 2010 20
Figure 5: In Vitro Diagnostics, Sweden, Cross-Category Analysis, 2003-2017 21
Figure 6: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, Historic, 2003-2010 23
Figure 7: In Vitro Diagnostics, Sweden, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 25
Figure 8: In Vitro Diagnostics, Sweden, Company share (%), 2010 27
Figure 9: Clinical Chemistry, Market Segmentation 29
Figure 10: Clinical Chemistry Market, Sweden, Revenue Mix ($m), 2010 30
Figure 11: Clinical Chemistry Market, Sweden, Segment Contribution (%), 2010 31
Figure 12: Clinical Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 32
Figure 13: Clinical Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 34
Figure 14: Clinical Chemisty Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 36
Figure 15: Clinical Chemisty Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 38
Figure 16: Urine Analysis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 40
Figure 17: Urine Analysis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 42
Figure 18: Clinical Chemistry, Sweden, Company share (%), 2010 45
Figure 19: Genetic Testing, Market Segmentation 47
Figure 20: Genetic Testing Market, Sweden, Revenue Mix ($m), 2010 48
Figure 21: Genetic Testing Market, Sweden, Segment Contribution (%), 2010 49
Figure 22: Genetic Testing, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 50
Figure 23: Genetic Testing, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 52
Figure 24: Genetic Testing, Sweden, Company share (%), 2010 55
Figure 25: Haematology, Market Segmentation 57
Figure 26: Haematology Market, Sweden, Revenue Mix ($m), 2010 58
Figure 27: Haematology Market, Sweden, Segment Contribution (%), 2010 59
Figure 28: Haematology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 60
Figure 29: Haematology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 62
Figure 30: Haematology Reagents, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 64
Figure 31: Haematology Reagents, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 66
Figure 32: Immunohaematology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 68
Figure 33: Immunohaematology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 70
Figure 34: Haemostasis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 72
Figure 35: Haemostasis, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 74
Figure 36: Haematology Rapid Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 76
Figure 37: Haematology Rapid Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 78
Figure 38: Haematology Cell Counters, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Figure 39: Haematology Cell Counters, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Figure 40: Haematology, Sweden, Company share (%), 2010 85
Figure 41: Histology And Cytology, Market Segmentation 87
Figure 42: Histology And Cytology Market, Sweden, Revenue Mix ($m), 2010 88
Figure 43: Histology And Cytology Market, Sweden, Segment Contribution (%), 2010 89
Figure 44: Histology And Cytology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 90
Figure 45: Histology And Cytology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 92
Figure 46: Histology And Cytology, Sweden, Company share (%), 2010 95
Figure 47: Immuno Chemistry Market, Sweden, Revenue Mix ($m), 2010 97
Figure 48: Immuno Chemistry Market, Sweden, Segment Contribution (%), 2010 98
Figure 49: Immuno Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 99
Figure 50: Immuno Chemistry, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 101
Figure 51: Disease Specific Immunochemistry, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 103
Figure 52: Disease Specific Immunochemistry, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 105
Figure 53: Drugs of Abuse / Toxicology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 107
Figure 54: Drugs of Abuse / Toxicology, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 109
Figure 55: Endocrinology Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 111
Figure 56: Endocrinology Tests, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 113
Figure 57: Therapeutic Drug Monitoring, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115
Figure 58: Therapeutic Drug Monitoring, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117
Figure 59: Immunochemistry Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 119
Figure 60: Immunochemistry Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 121
Figure 61: Immuno Chemistry, Sweden, Company share (%), 2010 124
Figure 62: Infectious Immunology, Market Segmentation 126
Figure 63: Infectious Immunology Market, Sweden, Revenue Mix ($m), 2010 127
Figure 64: Infectious Immunology Market, Sweden, Segment Contribution (%), 2010 128
Figure 65: Infectious Immunology, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 129
Figure 66: Infectious Immunology, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 131
Figure 67: Infectious Immunology, Sweden, Company share (%), 2010 134
Figure 68: Microbiology Culture, Market Segmentation 136
Figure 69: Microbiology Culture Market, Sweden, Revenue Mix ($m), 2010 137
Figure 70: Microbiology Culture Market, Sweden, Segment Contribution (%), 2010 138
Figure 71: Microbiology Culture, Sweden, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 139
Figure 72: Microbiology Culture, Sweden, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 141
Figure 73: Microbiology Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 143
Figure 74: Microbiology Analyzers, Sweden, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 145
Figure 75: Microbiology Culture, Sweden, Company share (%), 2010 148
Figure 76: F. Hoffmann-La Roche Ltd., Company Share (%),Sweden In Vitro Diagnostics Market, 2010 150
Figure 77: Siemens Healthcare, Company Share (%),Sweden In Vitro Diagnostics Market, 2010 151
Figure 78: Abbott Laboratories, Company Share (%),Sweden In Vitro Diagnostics Market, 2010 152
Figure 79: bioMerieux S.A., Company Share (%),Sweden In Vitro Diagnostics Market, 2010 153
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Sweden In Vitro Diagnostics Market, 2010 154
Figure 81: Beckman Coulter, Inc., Company Share (%),Sweden In Vitro Diagnostics Market, 2010 155
[Tabellenverzeichnis ausblenden]